Welcome to our dedicated page for Corvus Pharmaceu news (Ticker: CRVS), a resource for investors and traders seeking the latest updates and insights on Corvus Pharmaceu stock.
Corvus Pharmaceuticals reports clinical, financing, governance, and financial updates for a clinical-stage biopharmaceutical company developing ITK inhibition as an immunotherapy approach for immune diseases and cancer. Its lead candidate, soquelitinib, is an investigational oral small molecule designed to selectively inhibit interleukin-2-inducible T cell kinase, a protein involved in T cell activation, signaling, differentiation, and function.
Recurring company news centers on soquelitinib clinical development in relapsed/refractory peripheral T cell lymphoma and atopic dermatitis, including immunologic and biomarker data presented at medical meetings. Updates also cover business results, public equity financing for research and development, board composition, and other clinical-stage pipeline disclosures.
BURLINGAME, Calif., May 13, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals (NASDAQ: CRVS) announced the upcoming presentation of updated data on the Adenosine Gene Signature as a predictive biomarker for patients treated with ciforadenant, an A2A receptor antagonist. This data will be presented at the ASCO20 Virtual Scientific Program from May 29-31, 2020. Findings from the Phase 1b/2 trial in advanced refractory renal cell cancer indicate that CD68 positive myeloid cells may enhance patient selection. The poster presentation will be available for on-demand viewing starting May 29, 2020.
Corvus Pharmaceuticals (NASDAQ: CRVS) reported Q1 2020 business updates and financial results on April 30, 2020. The company achieved significant patient enrollment across three clinical programs. Key developments include positive data for ciforadenant, the Adenosine Gene Signature, and CPI-818. Corvus holds a strong position in targeting the adenosine pathway in oncology. Financially, Corvus reported a net loss of $12.9 million and cash reserves of $68.7 million. The company revised its 2020 operational cash forecast to $29-31 million due to COVID-19 impacts.